Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $67.63 Consensus Price Target from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have received an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $67.6250.

Several analysts have recently commented on DNTH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Jefferies Financial Group upped their price objective on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Truist Financial lifted their target price on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. HC Wainwright boosted their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Wedbush raised their price target on Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th.

Dianthus Therapeutics Stock Up 3.9%

Shares of NASDAQ DNTH opened at $55.19 on Wednesday. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $57.50. The firm’s 50-day simple moving average is $46.72 and its 200 day simple moving average is $39.43. The company has a market cap of $2.39 billion, a price-to-earnings ratio of -15.86 and a beta of 1.56.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 16.56% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNTH. Seven Fleet Capital Management LP bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at $604,000. Invesco Ltd. grew its stake in shares of Dianthus Therapeutics by 125.9% during the fourth quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock worth $4,182,000 after purchasing an additional 56,560 shares during the period. XTX Topco Ltd bought a new stake in Dianthus Therapeutics in the fourth quarter valued at about $550,000. Voloridge Investment Management LLC lifted its stake in Dianthus Therapeutics by 80.5% in the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock valued at $1,627,000 after buying an additional 17,612 shares during the period. Finally, Virtus Investment Advisers LLC lifted its stake in Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after buying an additional 416 shares during the period. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.